Health Care • Medical Specialities
$29.46 ▼ -0.05
(-0.17%)
MKT CAP: $2.74B • VOL: 2.74M
52W L $11 52W H $36
ACHC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.31B | $3.15B | $2.93B |
| YoY Revenue Growth % | +5.0% | +7.7% | — |
| Gross Profit | $1.46B | $1.39B | $1.29B |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.30B | $301.6M | -$25.6M |
| Operating Margin % | -39.3% | 9.6% | -0.9% |
| Net Income (GAAP) | -$1.10B | $255.6M | -$21.7M |
| EBITDA (Normalized) | -$843.8M | $853.9M | $79.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $131.9M | $129.7M | $462.3M |
| Capital Expenditures (CapEx) | $571.8M | $690.4M | $131.8M |
| Free Cash Flow (FCF) | -$439.9M | -$560.7M | $330.5M |
| FCF Margin % | -13.3% | -17.8% | 11.3% |
| Return on Invested Capital (ROIC %) | -24.0% | 4.9% | -1.0% |
| Cash & Short-Term Equivalents | $133.2M | $76.3M | $386.6M |
| Total Debt (Short + Long Term) | $2.47B | $1.88B | $822.4M |
| Total Stockholders' Equity | $1.95B | $3.07B | $1.69B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACHC.